Another 2024 study, involving more than 400,000 patients in the Netherlands, found that people with Type 2 diabetes who used semaglutide had more than double the risk of developing NAION compared to those who didnt take the drug
It works by mimicking a hormone called GLP-1 (glucagon-like peptide-1) that targets areas of the brain responsible for appetite and food intake
Thats going to be different from person to person, but we know that, in general, people who lose weight have less of these chronic disorders heart disease, neurodegeneration, [and] diabetes
Rather than providing synthetic hormones directly, it encourages your body to regulate growth hormone production naturally, which leads to fewer risks and a more balanced hormonal response
Gastroparesis with bezoar formation in patients treated with glucagon-like peptide-1 receptor agonists: potential relevance for bariatric and other gastric surgery
In fact, one clinical study of obese patients published in Nature Metabolism in 2023 found that those treated with liraglutide saw significant improvement in a range of associative learning tasks versus the placebo group